by Elena Iemma | Apr 2, 2026 | News
EpiVax Enters its Next Chapter with SV Health Investors EpiVax today announced its acquisition by SV Health Investors (SVHI), a healthcare and life sciences-focused private investment firm. This milestone marks an exciting new chapter and will accelerate further...
by Elena Iemma | Jan 12, 2026 | Blog, News
In 2025, EpiVax advanced the science of immunogenicity assessment through AI-driven ADA prediction, enhanced in silico tools, expanded in vitro assays and consulting offerings, and new regulatory frameworks supporting biologics and generic peptides. Advancing...
by Elena Iemma | Dec 8, 2025 | News
EpiVax and FDA Scientists Publish New Insights on Immunogenicity Risks of Peptide-Related Impurities in Generic Teriparatide PROVIDENCE, R.I., Dec. 8, 2025 — EpiVax, Inc., with U.S. Food and Drug Administration (FDA) and CUBRC, Inc. (Buffalo, NY) scientist...
by Elena Iemma | May 28, 2025 | News
EpiVax Appoints Dr. Vibha Jawa to Lead Scientific Strategy as CSO PROVIDENCE, R.I., May 28, 2025 /PRNewswire/ — EpiVax, Inc., a leader in preclinical immunogenicity assessment for biologic therapeutics and vaccines, is pleased to announce the...
by Elena Iemma | Apr 21, 2025 | News
The Role of Treg Epitopes (Tregitopes) in Antibody Maturation Uncovered in New EpiVax Study: Implications for Therapeutic Antibodies PROVIDENCE, R.I., April 21, 2025 /PRNewswire/ — EpiVax, Inc. announces a new study published in Frontiers in Immunology unveiling...
by Elena Iemma | Feb 27, 2025 | News
EpiVax Strengthens Technology Leadership Amid Immunoinformatics Advancements PROVIDENCE, R.I., Feb. 27, 2025 — EpiVax, Inc. proudly announces the appointment of Guilhem Richard as Chief Technology Officer. Dr. Richard joined EpiVax’s immunoinformatics team in 2014 and...
